These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28499961)

  • 41. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus.
    Gibb RD; McRorie JW; Russell DA; Hasselblad V; D'Alessio DA
    Am J Clin Nutr; 2015 Dec; 102(6):1604-14. PubMed ID: 26561625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of Different Models of Structured Self-Monitoring of Blood Glucose in Type 2 Diabetes.
    Li CL; Wu YC; Kornelius E; Chen YJ; Lin YT; Hsiao HW; Peng CH; Yang YS; Huang CN
    Diabetes Technol Ther; 2016 Mar; 18(3):171-7. PubMed ID: 26950418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.
    Fowler GC; Vasudevan DA
    South Med J; 2010 Sep; 103(9):911-6. PubMed ID: 20689486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
    Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale, study design and methodology of the LANDMARC trial: a 3-year, pan-India, prospective, longitudinal study to assess management and real-world outcomes of diabetes mellitus.
    Das AK; Mithal A; Kumar KMP; Unnikrishnan AG; Kalra S; Thacker H; Sethi B; Ghosh R; Mathew A; Chodankar D; Mohanasundaram S; Menon SK; Trivedi C; Naqvi M; Kanade V; Salvi V; Chatterjee G; Rais N; Wangnoo SK; Chowdhury S; Zargar AH; Joshi S
    Diabet Med; 2020 May; 37(5):885-892. PubMed ID: 31691356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the "Diabetes Interactive Diary" telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes.
    Rossi MC; Nicolucci A; Lucisano G; Pellegrini F; Di Bartolo P; Miselli V; Anichini R; Vespasiani G;
    Diabetes Technol Ther; 2013 Aug; 15(8):670-9. PubMed ID: 23844569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of Continuous Subcutaneous Insulin Infusion Therapy on Efficacy and Safety in a Cohort of Type 1 Diabetes Patients: A 3-Year Prospective Study.
    Melidonis A; Kamaratos A; Angelidi A; Thomakos P; Vrakas S; Bakalis J; Fousteris E; Iraklianou S
    Diabetes Technol Ther; 2016 Mar; 18(3):159-63. PubMed ID: 26862678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Care delivery in youth with type 2 diabetes - are we meeting clinical practice guidelines?
    Amed S; Nuernberger K; Reimer K; Krueger H; Aydede SK; Ayers D; Collet JP
    Pediatr Diabetes; 2014 Nov; 15(7):477-83. PubMed ID: 24888460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
    Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
    Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study.
    Bongaerts B; Arnold SV; Charbonnel BH; Chen H; Cooper A; Fenici P; Gomes M; Ji L; Khunti K; Kosiborod M; Medina J; Nicolucci A; Shestakova M; Shimomura I; Tang F; Watada H; Rathmann W
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ISPAD Clinical Practice Consensus Guidelines 2014. Sick day management in children and adolescents with diabetes.
    Brink S; Joel D; Laffel L; Lee WW; Olsen B; Phelan H; Hanas R;
    Pediatr Diabetes; 2014 Sep; 15 Suppl 20():193-202. PubMed ID: 25182314
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B; Ahrén B; Neubacher D; Patel S; Woerle HJ; Johansen OE
    Can J Diabetes; 2016 Feb; 40(1):50-7. PubMed ID: 26474870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.